FDA shelves fast-track drug review initiative launched under Makary

The FDA has discontinued the fast-track drug review program initiated in June 2025 by former Commissioner Marty Makary. This marks a reversal of a key policy from the previous administration, signaling a shift in regulatory priorities. The move could affect drug approval timelines and industry expectations, though the full scope of impact remains unclear.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works